Samsca and Malacoplakia vesicae - a phase IV clinical study of FDA data
Summary:
We study 8,186 people who take Samsca (tolvaptan) or have Malacoplakia vesicae. No report of Malacoplakia vesicae is found in people who take Samsca.
The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.
What is Samsca?
Samsca has active ingredients of tolvaptan. eHealthMe is studying from 8,139 Samsca users. Check the latest studies of Samsca.
What is Malacoplakia Vesicae?
Malacoplakia vesicae (a flat yellow growth on the mucosa of the bladder) is found to be associated with 9 drugs and 19 conditions by eHealthMe. Check the latest studies of Malacoplakia vesicae.
No report is found.
Do you take Samsca and have Malacoplakia vesicae?
- Check whether Malacoplakia vesicae is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Samsca:
- Samsca (8,139 reports)
Malacoplakia vesicae treatments and more:
- Malacoplakia vesicae (47 reports)
How severe was Malacoplakia vesicae and when was it recovered:
Expand to all the drugs that have ingredients of tolvaptan:
Browse all side effects of Samsca:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Malacoplakia vesicae:
Browse all the conditions that are associated with Malacoplakia vesicae:
How the study uses the data?
The study uses data from the FDA. It is based on tolvaptan (the active ingredients of Samsca) and Samsca (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Central Nervous System Lymphoma and Epilepsy - a second ago
- Drug interactions of Vitamin B1 and Nitrostat - 17 seconds ago
- Drug interactions of Zolpidem and Herceptin - 24 seconds ago
- Drug interactions of Tegretol and Heparin - 32 seconds ago
- Drug interactions of Latanoprost and Glycopyrrolate - 35 seconds ago
- Drug interactions of Perindopril Erbumine and Enoxaparin Sodium - 36 seconds ago
- Drug interactions of Carpine and Evista - 36 seconds ago
- Drug interactions of Anafranil and Ambien - 39 seconds ago
- Brain Neoplasm Malignant and Headache - 39 seconds ago
- Could Rubraca cause Appetite Disorder? - 39 seconds ago